Tharimmune, Inc. (THAR)
| Market Cap | 2.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.20M |
| Shares Out | 2.11M |
| EPS (ttm) | -9.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,198 |
| Open | 1.120 |
| Previous Close | 1.100 |
| Day's Range | 1.115 - 1.130 |
| 52-Week Range | 0.952 - 6.450 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+1,404.56%) |
| Earnings Date | May 8, 2025 |
About THAR
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minot... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for THAR stock is "Strong Buy" and the 12-month stock price forecast is $17.0.
News
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the ap...
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today...
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway -Company leveraging existing human pharmacokinetic data with TH104 -Advancing CMC plan to meet requirements of ...
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, toda...
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today...
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immun...
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunolog...
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
BRIDGEWATER, NJ / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology...
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events Phase 2 preliminary data for chronic pruritus in pr...
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidat...
Tharimmune Announces Upcoming Conference Presentations
BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidate...
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidate...
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profile TH104 was well tolerated with no unexpecte...
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
- Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth - ...
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of ther...
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc . (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates ...
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates i...
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Pharmacokinetic profile of oral transmucosal delivery of TH104 was comparable to intravenous delivery of reference drug Positive safety/tolerability achieved with TH104 reporting a mild side-effect pr...
Tharimmune To Participate in Two Upcoming Investor Conferences in May
BRIDGEWATER, NJ / ACCESSWIRE / April 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates ...
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Obtained rights from Washington University to develop and incorporate human HER2 directed antibodies Complements early pipeline of novel tunable "Knob domain" antibodies for HER2 & HER3 BRIDGEWATER, N...
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation BRIDGEWATER, NJ / ACCESSWIRE / April ...
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
Tharimmune invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference BRIDGEWATER, NJ / ACCESS...
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studies Phase 1 clinical trial compared oral transmucosal delivery of TH...
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104 Phase 1 study expected to be completed in 1Q24 with topli...
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Phase 1 trial initiated to assess safety/tolerability and absolute bioavailability of TH104 with topline data expected in 2Q24 Planning well underway for Phase 2 of TH104 in primary biliary cholangiti...